Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
5
83%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

terminated233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

NCT01225172
completedphase_1

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

NCT00569036
terminatedphase_1

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

NCT00908024
completedphase_1

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

NCT00788333
completedphase_1

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT00793897
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01225172Phase 2

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Terminated
NCT00569036Phase 1

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Completed
NCT00908024Phase 1

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Terminated
NCT00788333Phase 1

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Completed
NCT00793897Phase 1

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Completed
NCT00898716Phase 1

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6